1-3 of 3
ocrelizumab
Close
Sort by
Journal Articles

Protein Tomography Analysis Shows That CD20 Molecules Bound by Different Type I and Type II Anti-CD20 Antibodies Are Organized in Different Protein Complexes.

Gerhard J Niederfellner, Annika Braennstroem, Frida Lindstrom, Magnus Jansson, Marika Lundin, Wolfgang Schaefer, Olaf Mundigl, Pablo Umana, Christian Klein
Journal: Blood
Blood (2009) 114 (22): 4782.
https://doi.org/10.1182/blood.V114.22.4782.4782
Published: 2009
Journal Articles

Crystal Structure Analysis Reveals That the Novel Type II Anti-CD20 Antibody GA101 Interacts with a Similar Epitope as Rituximab and Ocrelizumab but in a Fundamentally Different Way.

Gerhard J Niederfellner, Alfred Lammens, Manfred Schwaiger, Guy Georges, Kornelius Wiechmann, Andreas Franke, Wolfgang Schaefer, Stefan Jenewein, Jerry Slootstra, Ekkehard Moessner, Pablo Umana, Karl-Peter Hopfner, Christian Klein
Journal: Blood
Blood (2009) 114 (22): 3726.
https://doi.org/10.1182/blood.V114.22.3726.3726
Published: 2009
Journal Articles

Interim Results of a Phase I/II Study of Ocrelizumab, a New Humanised Anti-CD20 Antibody in Patients with Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma.

Franck Morschhauser, Paula Marlton, Umberto Vitolo, Ola Linden, John Seymour, Michael Crump, Bertrand Coiffier, Alessandro Pulsoni, Andrew Belch, Erika Lerch, Eva Kimby, Kristina Arnljots, Elisabeth Wassner, Myriam Mendila
Journal: Blood
Blood (2007) 110 (11): 645.
https://doi.org/10.1182/blood.V110.11.645.645
Published: 2007